NEW YORK – SomaLogic said today that is has entered a new agreement with drugmaker Novartis to use its SomaScan proteomics platform in drug discovery and development efforts.
Under the agreement, which is slated to last 10 years, SomaLogic will analyze at least 250,000 clinical samples provided by Novartis and use the data from these analyses to drive its own proteomic test development work.
The deal builds on the previous relationship between the two companies, which began in 2011 with an initial agreement followed by and expansion of that agreement in 2014, in which Novartis took an equity stake in Somalogic.
"Our ongoing collaboration with our Novartis colleagues … has been instrumental in both developing and validating the value of our SomaScan platform," SomaLogic CEO Roy Smythe said in a statement. "Today, our technology is being used to inform research efforts around the world, promote individual health and wellness, and augment clinical decision-making."
"By continuing our collaboration with SomaLogic and incorporating proteomics into our development programs, alongside our genomics capabilities and deep analysis of our vast historical data resources, we aim to achieve unprecedented insight into human physiology," said John Tsai, head of global drug development and chief medical officer at Novartis. "Deciphering the complex interaction of protein networks in the body could unlock an additional therapeutic approach for treating the unmet needs of patients."
Financial and other terms of the agreement were not disclosed.